Leanabl 2026 Global Presence: Seoul, US, EU, APAC Coverage

Announcement

Leanabl Inc. announced today its 2026 global presence strategy, formalizing operations across Korea, North America, Europe, and APAC to support multinational medical device manufacturers entering Korean and global markets.

Current Operational Footprint

🇰🇷 Seoul, South Korea (Headquarters)

Founded 2022
Address: 111 Ogeum-ro, Songpa-gu, Rm 801-B1, Segi Bldg, 05548
Core team: regulatory affairs, KLH operations, KGMP advisory
Korean clinical KOL network

🇺🇸 United States

Client engagements: US-headquartered medical device manufacturers
FDA 510(k), De Novo, PMA pathway expertise
US-to-Korea parallel submission strategy

🇪🇺 European Union

Client engagements: EU MDR-cleared manufacturers entering Korea
CE Mark to MFDS conversion expertise
EU MDR Article 117 + Korean equivalence strategy

🇯🇵 Japan

PMDA + MFDS Asia-Pacific dual-market strategy
Japanese language support for Japanese manufacturers entering Korea
Korean device entry for Japanese manufacturers

🇨🇳 China

NMPA + MFDS Asia regulatory comparison
Chinese manufacturer Korean market entry support

What Global Presence Means for Clients

Unified Regulatory Strategy

Clients benefit from coordinated multi-jurisdiction strategy:

FDA + MFDS parallel submission planning
EU MDR + MFDS submission with shared documentation
PMDA + MFDS APAC strategy
NMPA + MFDS for Chinese manufacturers

Local-Hour Communication

Korea-based core team supports:

Korean business hours (KST) for direct Korean operations
Western business hours (PST/EST/CET) through extended team coordination
24-hour vigilance response for adverse event reporting

Regional Regulatory Insight

Active engagements across regions provide:

Real-time intelligence on regulatory changes
Comparative analysis across jurisdictions
Best-practice cross-pollination

2026 Expansion Plans

Leanabl plans to formalize partner relationships in:

EU: Munich-based regulatory partner for EU MDR + Korean dual-market support
APAC: Singapore-based regulatory partner for ASEAN coordination
North America: Boston-based partner for US medical device community presence
Japan: Tokyo-based partner for PMDA collaboration

These additions strengthen Leanabl's ability to support clients with multi-jurisdiction regulatory strategy from a single coordinated team.

Service Coverage by Region

Region	Service Coverage
🇰🇷 Korea	All services — MFDS, KGMP, KLH, vigilance, HIRA
🇺🇸 US	Strategic services — FDA coordination, KLH for US manufacturers
🇪🇺 EU	Strategic services — EU MDR coordination, KLH for EU manufacturers
🇯🇵 Japan	Strategic services — PMDA coordination, KLH for Japanese manufacturers
🇨🇳 China	Strategic services — NMPA coordination, KLH for Chinese manufacturers

Leanabl's Commitment

"Our global presence isn't about offices — it's about being where our clients need regulatory expertise. Whether you're a Boston startup entering Korea or a Munich-based EU MDR manufacturer planning APAC expansion, we provide unified strategy from a single coordinated team," said Stephen Jeong, Founder of Leanabl.

How to Engage Leanabl

For Medical Device Manufacturers

Korea market entry strategy
Multi-jurisdiction regulatory planning
KLH (Korea License Holder) services
KGMP and quality system advisory
Post-market vigilance and reimbursement

For Strategic Partners

Leanabl welcomes strategic partnerships with:

Regional regulatory consultancies
Health technology assessment firms
Korean clinical investigation organizations
Distributors with regulatory ambitions

About Leanabl

Leanabl is a medical device regulatory consulting firm specializing in Korea (MFDS) market entry for foreign manufacturers. Founded in 2022 in Seoul, Leanabl provides end-to-end services including MFDS product registration, KGMP certification, Korea License Holder (KLH) services, post-market vigilance, and HIRA reimbursement.

Learn more:

Media Inquiries

info@leanabl.com
Stephen Jeong, Founder
Leanabl Inc., Seoul, South Korea

Released: 2026-03-15.